Synthesis and anti-HIV activity of 4'-cyano-2',3'-didehydro-3'-deoxythymidine. 2004

Kazuhiro Haraguchi, and Yoshiharu Itoh, and Shingo Takeda, and Yosuke Honma, and Hiromichi Tanaka, and Takao Nitanda, and Masanori Baba, and Ginger E Dutschman, and Yung-Chi Cheng
School of Pharmaceutical Sciences, Showa University, Shinagawa-ku, Tokyo, Japan. harakazu@pharm.showa-u.ac.jp

A new anti-HIV agent 4'-cyano-2',3'-didehydro-3'-deoxythymidine (9) was synthesized by allylic substitution of the 3',4'-unsaturated nucleoside 14, having a leaving group at the 2'-position, with cyanotrimethylsilane in the presence of SnCl4. Evaluation of the anti-HIV activity of 9 showed that this compound is much less potent than the recently reported 2',3'-didehydro-3'-deoxy-4'-(ethynyl)thymidine (1).

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013936 Thymidine A nucleoside in which THYMINE is linked to DEOXYRIBOSE. 2'-Deoxythymidine,Deoxythymidine,2' Deoxythymidine
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D018119 Stavudine A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. 2',3'-Didehydro-3'-deoxythymidine,D4T,2',3'-Didehydro-2',3'-dideoxythmidine,BMY-27857,Stavudine, Monosodium Salt,Zerit,2',3' Didehydro 3' deoxythymidine,BMY 27857,BMY27857
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

Kazuhiro Haraguchi, and Yoshiharu Itoh, and Shingo Takeda, and Yosuke Honma, and Hiromichi Tanaka, and Takao Nitanda, and Masanori Baba, and Ginger E Dutschman, and Yung-Chi Cheng
July 1999, Bioorganicheskaia khimiia,
Kazuhiro Haraguchi, and Yoshiharu Itoh, and Shingo Takeda, and Yosuke Honma, and Hiromichi Tanaka, and Takao Nitanda, and Masanori Baba, and Ginger E Dutschman, and Yung-Chi Cheng
January 2002, Organic letters,
Kazuhiro Haraguchi, and Yoshiharu Itoh, and Shingo Takeda, and Yosuke Honma, and Hiromichi Tanaka, and Takao Nitanda, and Masanori Baba, and Ginger E Dutschman, and Yung-Chi Cheng
January 1990, Drug metabolism and disposition: the biological fate of chemicals,
Kazuhiro Haraguchi, and Yoshiharu Itoh, and Shingo Takeda, and Yosuke Honma, and Hiromichi Tanaka, and Takao Nitanda, and Masanori Baba, and Ginger E Dutschman, and Yung-Chi Cheng
July 1998, Bioorganic & medicinal chemistry letters,
Kazuhiro Haraguchi, and Yoshiharu Itoh, and Shingo Takeda, and Yosuke Honma, and Hiromichi Tanaka, and Takao Nitanda, and Masanori Baba, and Ginger E Dutschman, and Yung-Chi Cheng
June 1995, Antiviral research,
Kazuhiro Haraguchi, and Yoshiharu Itoh, and Shingo Takeda, and Yosuke Honma, and Hiromichi Tanaka, and Takao Nitanda, and Masanori Baba, and Ginger E Dutschman, and Yung-Chi Cheng
December 1993, Journal of pharmaceutical sciences,
Kazuhiro Haraguchi, and Yoshiharu Itoh, and Shingo Takeda, and Yosuke Honma, and Hiromichi Tanaka, and Takao Nitanda, and Masanori Baba, and Ginger E Dutschman, and Yung-Chi Cheng
March 1994, Journal of pharmaceutical sciences,
Kazuhiro Haraguchi, and Yoshiharu Itoh, and Shingo Takeda, and Yosuke Honma, and Hiromichi Tanaka, and Takao Nitanda, and Masanori Baba, and Ginger E Dutschman, and Yung-Chi Cheng
January 2003, Journal of medicinal chemistry,
Kazuhiro Haraguchi, and Yoshiharu Itoh, and Shingo Takeda, and Yosuke Honma, and Hiromichi Tanaka, and Takao Nitanda, and Masanori Baba, and Ginger E Dutschman, and Yung-Chi Cheng
January 1990, Journal of medicinal chemistry,
Kazuhiro Haraguchi, and Yoshiharu Itoh, and Shingo Takeda, and Yosuke Honma, and Hiromichi Tanaka, and Takao Nitanda, and Masanori Baba, and Ginger E Dutschman, and Yung-Chi Cheng
November 2003, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!